RxDoctor Payments DataLook up a doctor →

Carlos Mena-Hurtado, MD

Cardiovascular Disease · New Haven, CTNPI 1205800273

Payments from drug & device makers

$665,161in general payments, 2019–2025

Across 406 payments — averaging $1638.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Incorporated$118K
  • Abbott$69K
  • Shockwave Medical, Inc$62K
  • Cardiva Medical, Inc.$58K
  • Surmodics, Inc.$47K
  • Medtronic$44K
  • plus $268K from 21 others
$18,320in research payments, 2019–2025

Across 5 payments — averaging $3664.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$18K

What the payments were for

  • Consulting fees$238,53852%
  • Speaking & faculty fees$171,59037%
  • Travel & lodging$42,3789%
  • Food & beverage$7,6552%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$665,161 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$240,582
Medicare patients
571
Services billed
2,502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban19$23,600
EliquisApixaban23$20,972
BrilintaTicagrelor13$12,862
Praluent PenAlirocumab15$8,276
ClopidogrelClopidogrel Bisulfate112$1,303
Cilostazol16$577
Atorvastatin Calcium56$550
Rosuvastatin Calcium40$497
Ezetimibe18$338
Carvedilol15$202
Metoprolol Succinate25$195
Losartan Potassium29$195
Furosemide40$136
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$133
Lisinopril23$111

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →